KLRK1 and multiple sclerosis: NKG2D-based CARs can recognize NKG2D ligands expressed on several human tumor types, but these ligands are also expressed in some immune-mediated diseases such as rheumatoid arthritis, in celiac and inflammatory bowel diseases and in multiple sclerosis, which raises concerns about “on-target off-tumor” toxicity [86].